Research in the UAE

Managing MS Treatment During Family Planning

Published on Sat, 20 Jun 2020

Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region

Managing multiple sclerosis (MS) during pregnancy poses challenges due to the risks of disease-modifying drugs (DMDs). Gulf-based experts recommend continuing safer treatments like interferon β, glatiramer acetate, and, in specific cases, natalizumab until 30 weeks of gestation. Immune reconstitution therapies, like cladribine and alemtuzumab, require planning due to prolonged washout periods. Interferon β is also deemed safe for breastfeeding. Experts highlight the need for individualized approaches to balance disease activity management and family planning while addressing data gaps for certain DMDs during breastfeeding.

Related research

Learn More
Switching from Fingolimod/Natalizumab to Cladribine Without Rebound
Fri, 1 Dec 2023

Switching from Fingolimod/Natalizumab to Cladribine Without Rebound

Learn More
Learn More
Adherence Challenges for High-Efficacy MS Therapies
Fri, 22 May 2020

Adherence Challenges for High-Efficacy MS Therapies

Learn More
Learn More
Living with MS: A Biopsychosocial Perspective
Tue, 17 Aug 2021

Living with MS: A Biopsychosocial Perspective